Physical Medicine & Rehabilitation, Pain Medicine · Brooklyn, NY
NPI
1497825434
Since 2006
Specialty
Physical Medicine & Rehabilitation, Pain Medicine
Code 2081P2900X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
5223 9th Ave
Brooklyn, NY, 11220
Phone (718) 431-2959
Groups this clinician bills Medicare through
Medicare paid, 2024
$453K
7,788 services
Medicare patients, 2024
504
Average age 72
Drug cost, 2024
$1.4M
9,182 prescriptions
Company payments, 2025
$673
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Isaac Kreizman was code J3301 (injection, triamcinolone acetonide, not otherwise specified, 10 mg), 3,276 times for 353 patients. In total Isaac Kreizman billed 7,788 services in 35 codes, and Medicare paid $453K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-08-03.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 3,276 | 353 | $0.77 | $2,527 |
| 99213 Office E&M - Established | Office | 737 | 201 | $70.65 | $52K |
| J7321 Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | Office | 668 | 112 | $57.68 | $39K |
| 20610 Joint Injection | Office | 467 | 137 | $70.37 | $33K |
| 77002 Imaging - Miscellaneous | Office | 453 | 135 | $97.43 | $44K |
| 64484 Nerve Block Injection - Back | Office | 386 | 245 | $93.50 | $36K |
| 64483 Nerve Block Injection - Back | Office | 386 | 245 | $202.35 | $78K |
| 95886 Electrical Nerve Conductivity | Office | 362 | 154 | $79.61 | $29K |
| 64480 Nerve Block Injection - Back | Office | 224 | 145 | $112.66 | $25K |
| 64479 Nerve Block Injection - Back | Office | 224 | 145 | $219.01 | $49K |
| 95911 Electrical Nerve Conductivity | Office | 181 | 154 | $170.48 | $31K |
| 76942 Ultrasound - Nonspecific | Office | 135 | 85 | $23.37 | $3,155 |
| 99203 Office E&M - New | Office | 99 | 99 | $85.83 | $8,498 |
| 64450 Musculoskeletal | Office | 65 | 42 | $60.06 | $3,904 |
| 64520 Nerve Block Injection - Back | Office | 56 | 38 | $188.33 | $11K |
By year: 2022 $728K for 11,275 services; 2023 $577K for 8,793 services; 2024 $453K for 7,788 services.
Medicare prescription drug claims, 2024
In 2024, the drug Isaac Kreizman prescribed most often to Medicare patients was Gabapentin, with 1,181 prescriptions and refills. In total Isaac Kreizman wrote 9,182 Medicare prescriptions that cost $1.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Gabapentin Generic | 1,181 | 1,220 | 287 | $7,046 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 1,145 | 1,145 | 122 | $93K |
| Diclofenac Sodium Generic | 920 | 944 | 274 | $255K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 414 | 414 | 80 | $9,561 |
| Oxycodone Hcl Generic | 414 | 414 | 46 | $8,011 |
| Zolpidem Tartrate Generic | 313 | 313 | 43 | $2,109 |
| Morphine Sulfate Er Morphine Sulfate | 296 | 296 | 40 | $7,830 |
| Naproxen-Esomeprazole Mag Naproxen/Esomeprazole Mag | 289 | 305 | 45 | $334K |
| Amitriptyline Hcl Generic | 286 | 306 | 60 | $2,533 |
| Tizanidine Hcl Generic | 278 | 280 | 70 | $1,855 |
| Tramadol Hcl Generic | 275 | 275 | 107 | $2,025 |
| Cyclobenzaprine Hcl Generic | 225 | 225 | 64 | $1,710 |
| Lidocaine Generic | 223 | 238 | 42 | $22K |
| Methadone Hcl Generic | 202 | 202 | 25 | $6,607 |
| Duloxetine Hcl Generic | 193 | 203 | 53 | $1,896 |
Brand drugs: 761 claims; generic drugs: 8,421 claims; opioid claims: 3,145.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Isaac Kreizman $673 ($673 in general payments such as food, travel and fees) from 5 companies. The largest payer was Salix Pharmaceuticals, a division of Bausch Health US, LLC with $358.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.